Does the media favor UPB or AKTS?

In the previous week, Aktis Oncology had 3 more articles in the media than Upstream Bio. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Aktis Oncology's score of 0.15 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, UPB or MNKD?

MannKind has higher revenue and earnings than Upstream Bio. MannKind is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $2.85M 96.86 -$143.44M -$2.90 N/A MannKind $348.97M 3.50 $5.86M -$0.13 N/A

Is UPB or MNKD more profitable?

MannKind has a net margin of -11.08% compared to Upstream Bio's net margin of -4,955.67%. MannKind's return on equity of 0.00% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets Upstream Bio -4,955.67% -48.40% -46.57% MannKind -11.08% N/A -6.31%

Does the media favor UPB or MNKD?

In the previous week, MannKind had 6 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for MannKind and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat MannKind's score of 0.41 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SVRA or UPB more profitable?

Savara has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Upstream Bio -4,955.67% -48.40% -46.57%

Does the media refer more to SVRA or UPB?

In the previous week, Savara and Savara both had 2 articles in the media. Upstream Bio's average media sentiment score of 0.90 beat Savara's score of 0.45 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ODTX or UPB?

In the previous week, Upstream Bio had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Upstream Bio's score of 0.90 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLTX or UPB?

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Upstream Bio. MarketBeat recorded 6 mentions for MoonLake Immunotherapeutics and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat MoonLake Immunotherapeutics' score of 0.67 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Upstream Bio (UPB) Competitors

$5.04 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.04 +0.00 (+0.10%)

As of 10/2/2026 07:30 PM Eastern

Compare

UPB vs. AKTS, MNKD, SVRA, ODTX, and MLTX

Should you buy Upstream Bio stock or one of its competitors? Upstream Bio's main competitors and comparable companies include Aktis Oncology (AKTS), MannKind (MNKD), Savara (SVRA), Odyssey Therapeutics (ODTX), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Upstream Bio compare to Aktis Oncology?

Upstream Bio (NASDAQ:UPB) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

28.8% of Aktis Oncology shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Upstream Bio currently has a consensus price target of $29.67, indicating a potential upside of 488.62%. Aktis Oncology has a consensus price target of $35.63, indicating a potential upside of 92.36%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Aktis Oncology has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Aktis Oncology's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Aktis Oncology	N/A	N/A	N/A

Aktis Oncology has higher revenue and earnings than Upstream Bio. Aktis Oncology is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	96.86	-$143.44M	-$2.90	N/A
Aktis Oncology	$6.50M	153.15	-$63.73M	-$0.82	N/A

In the previous week, Aktis Oncology had 3 more articles in the media than Upstream Bio. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Aktis Oncology's score of 0.15 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aktis Oncology beats Upstream Bio on 12 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to MannKind?

Upstream Bio (NASDAQ:UPB) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

49.6% of MannKind shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Upstream Bio has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

MannKind has higher revenue and earnings than Upstream Bio. MannKind is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	96.86	-$143.44M	-$2.90	N/A
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A

Upstream Bio presently has a consensus target price of $29.67, indicating a potential upside of 488.62%. MannKind has a consensus target price of $8.34, indicating a potential upside of 119.57%. Given Upstream Bio's higher probable upside, equities analysts clearly believe Upstream Bio is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has a net margin of -11.08% compared to Upstream Bio's net margin of -4,955.67%. MannKind's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
MannKind	-11.08%	N/A	-6.31%

In the previous week, MannKind had 6 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for MannKind and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat MannKind's score of 0.41 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MannKind beats Upstream Bio on 10 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Savara?

Savara (NASDAQ:SVRA) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Savara and Savara both had 2 articles in the media. Upstream Bio's average media sentiment score of 0.90 beat Savara's score of 0.45 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara has higher earnings, but lower revenue than Upstream Bio. Savara is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Upstream Bio	$2.85M	96.86	-$143.44M	-$2.90	N/A

Savara has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Savara has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Savara presently has a consensus price target of $10.00, suggesting a potential upside of 107.90%. Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 488.62%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Upstream Bio beats Savara on 8 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Odyssey Therapeutics has higher earnings, but lower revenue than Upstream Bio. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Upstream Bio	$2.85M	96.86	-$143.44M	-$2.90	N/A

Odyssey Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Odyssey Therapeutics' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Upstream Bio	-4,955.67%	-48.40%	-46.57%

In the previous week, Upstream Bio had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Upstream Bio's score of 0.90 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Odyssey Therapeutics currently has a consensus target price of $35.75, suggesting a potential upside of 72.46%. Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 488.62%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Odyssey Therapeutics beats Upstream Bio on 6 of the 11 factors compared between the two stocks.

How does Upstream Bio compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics currently has a consensus target price of $28.50, indicating a potential upside of 149.78%. Upstream Bio has a consensus target price of $29.67, indicating a potential upside of 488.62%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Upstream Bio has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Upstream Bio	$2.85M	96.86	-$143.44M	-$2.90	N/A

MoonLake Immunotherapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Upstream Bio. MarketBeat recorded 6 mentions for MoonLake Immunotherapeutics and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat MoonLake Immunotherapeutics' score of 0.67 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Upstream Bio beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$276.05M	$3.86B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.74	13.06	275.67	26.04
Price / Sales	96.86	1,292.17	656.66	111.05
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.80	16.63	10.93	6.31
Net Income	-$143.44M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-5.97%	-2.99%	-2.00%	-1.66%
1 Month Performance	-16.14%	-10.81%	-6.19%	-4.68%
1 Year Performance	-72.95%	19.19%	8.03%	1.57%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	2.7466 of 5 stars	$5.04 flat	$29.67 +488.6%	-72.9%	$276.05M	$2.85M	N/A	75
AKTS Aktis Oncology	2.4923 of 5 stars	$22.11 +3.2%	$35.63 +61.1%	N/A	$1.15B	$6.50M	N/A	79	News Coverage Positive News Analyst Forecast
MNKD MannKind	2.3424 of 5 stars	$3.49 -0.3%	$8.34 +139.1%	-34.0%	$1.13B	$348.97M	N/A	592	High Trading Volume
SVRA Savara	1.8065 of 5 stars	$5.30 -2.8%	$10.00 +88.7%	+37.8%	$1.12B	N/A	N/A	70	News Coverage Analyst Downgrade
ODTX Odyssey Therapeutics	3.1982 of 5 stars	$23.34 +1.2%	$35.75 +53.2%	N/A	$1.11B	N/A	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. AKTS, MNKD, SVRA, ODTX, and MLTX

How does Upstream Bio compare to Aktis Oncology?

Summary

How does Upstream Bio compare to MannKind?

Summary

How does Upstream Bio compare to Savara?

Summary

How does Upstream Bio compare to Odyssey Therapeutics?

Summary

How does Upstream Bio compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. AKTS, MNKD, SVRA, ODTX, and MLTX

How does Upstream Bio compare to Aktis Oncology?

Do insiders & institutionals have more ownership in UPB or AKTS?

Do analysts prefer UPB or AKTS?

Is UPB or AKTS more profitable?

Which has better valuation and earnings, UPB or AKTS?

Does the media favor UPB or AKTS?

Summary

How does Upstream Bio compare to MannKind?

Do institutionals and insiders have more ownership in UPB or MNKD?

Which has more risk & volatility, UPB or MNKD?

Which has stronger earnings & valuation, UPB or MNKD?

Do analysts recommend UPB or MNKD?

Is UPB or MNKD more profitable?

Does the media favor UPB or MNKD?

Summary

How does Upstream Bio compare to Savara?

Does the media refer more to SVRA or UPB?

Which has higher valuation and earnings, SVRA or UPB?

Which has more volatility and risk, SVRA or UPB?

Do institutionals & insiders have more ownership in SVRA or UPB?

Is SVRA or UPB more profitable?

Do analysts rate SVRA or UPB?

Summary

How does Upstream Bio compare to Odyssey Therapeutics?

Which has better earnings and valuation, ODTX or UPB?

Is ODTX or UPB more profitable?

Does the media prefer ODTX or UPB?

Do analysts prefer ODTX or UPB?

Summary

How does Upstream Bio compare to MoonLake Immunotherapeutics?

Do insiders & institutionals have more ownership in MLTX or UPB?

Do analysts recommend MLTX or UPB?

Which has preferable valuation & earnings, MLTX or UPB?

Which has more risk & volatility, MLTX or UPB?

Is MLTX or UPB more profitable?

Does the media refer more to MLTX or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools